- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04753177
The Neoadjuvant Combined Hormone Therapy in Premenopausal Women With Locally Advanced ER+/HER2- Breast Cancer
Breast cancer take a leading position in the structure of morbidity and mortality from malignant tumors among women.
Today the interest of many scientists and pharmaceutical companies is focused on the study of metastatic breast cancer forms. While we obtain little experimental data and practical research about the treatment of locally advanced forms.
In this regard, the study of new neoadjuvant drug therapy regimen for estrogen-receptor positive breast cancer in premenopausal woman is very relevant.
The proposed research will be the absolutely innovative investigation worldwide.
The study will consist of two modes of treatment, combined hormone therapy with CDK4/6-ingibitors and chemotherapy (the control), each replicated four times in a randomized, complete block design.
This research aims to improve the results of treatment, namely to increase the percentage of successfully treated patients and reduce toxicity from treatment.
Primary study endpoints will include the frequency of objective response and complete pathomorphological response (according to the Miller-Payne classification).
Secondary endpoints will include a decrease of the Ki67 level in postoperative material compared to primary biopsy, the frequency of organ-preserving operation after neoadjuvant treatment and quality of life.
Study hypothesis: neoadjuvant combined hormone therapy with CDK4/6-ingibitors in premenopausal women with luminal breast cancer leads to at least the same results as neoadjuvant chemotherapy, but with less toxicity.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Locations
-
-
-
St-Peterburg, Russian Federation, 191456
- Saint Petersburg State Budgetary Healthcare Institution, City Clinical Oncology Dispensary
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Female
- Age ≥ 18 years
- Women with a newly diagnosed breast cancer who have not previously received specific treatment, with a tumor stage: cT1-3N1-2M0.
- Immunohistochemical tumor markers: ER-positive (ER+ is defined ≥ 10% and/or and Allred of 2 or more); HER2 negative (HER2 negative is defined as having an IHC of 1+ without ISH OR IHC 2+ and ISH non-amplified with ratio less than 2.0 and if reported, average HER2 copy number < 4 signals/cells OR ISH non-amplified with ratio less than 2.0 and if reported, average HER2 copy number < 4 signals/cells (without IHC)
- Premenopausal women.
- Signed consent to participate in a clinical trial.
- The consent of the patient to carry out, if possible, organ-preserving surgery with previous radiation therapy.
- General state of ECOG (PS) 0 or 1.
- Adequate Bone Marrow Function including:
Absolute Neutrophil Count (ANC) ≥1500/μL or ≥1.5 x109/L; Platelets ≥100000/μL or ≥100 x 109/L; Hemoglobin ≥ 9 g/dL.
- Adequate Renal Function including: Serum creatinine ≤ 1.5 x upper limit of normal (ULN) or estimated creatinine clearance ≥ 60 ml/min as calculated using the method standard for the institution.
- Adequate Liver Function, including all of the following parameters:
Total serum bilirubin ≤ 1.0 x ULN unless the subject has documented Gilbert syndrome (in which case up to 3 x ULN is acceptable) ; Aspartate and Alanine Aminotransferase (AST and ALT) ≤ 1.5 x ULN; Alkaline phosphatase ≤ 2.5 x ULN.
- Female subjects of child bearing potential and their partners, who are sexually active, must agree to the use of two highly effective forms of contraception in combination throughout the period of taking study treatment and for at least 90 days after last dose of study drug, or they must totally/truly abstain from any form of sexual intercourse. Use of oral hormonal contraceptive agents in this study is not permitted.
- Absence of mutations in the BRCA1 and BRCA2 genes (revealed by PCR blood analysis)
- Providing histological materials to determine the status of mutations in the PIK3CA gene
Exclusion Criteria:
- Primary multiple synchronous tumors (except for detected basal multiple cancer of the skin or cervix in situ, which can be radically treated without adjuvant treatment for breast cancer)
- HIV positive status
- Known hypersensitivity to study drugs or excipients.
- Pregnancy and lactation
- Any chronic disease in the acute stage
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Neoadjuvant combined hormone therapy
Ribocyclib, fulvestrant, triptorelin
|
Neoadjuvant treatment will last 24 weeks in both groups.
A follow-up examination will be carried out every 8 weeks.
In the group of combined hormone therapy, repeate cor-biopsy of the tumor is planned to assess the Ki-67
Neoadjuvant treatment will last 24 weeks in both groups.
A follow-up examination will be carried out every 8 weeks.
In the group of combined hormone therapy, repeate cor-biopsy of the tumor is planned to assess the Ki-67
|
Active Comparator: Chemotherapy (the control)
doxorubicin, cyclophosphamide, paclitaxel
|
Neoadjuvant treatment will last 24 weeks in both groups.
A follow-up examination will be carried out every 8 weeks.
In the group of combined hormone therapy, repeate cor-biopsy of the tumor is planned to assess the Ki-67
Neoadjuvant treatment will last 24 weeks in both groups.
A follow-up examination will be carried out every 8 weeks.
In the group of combined hormone therapy, repeate cor-biopsy of the tumor is planned to assess the Ki-67
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
frequency of objective response
Time Frame: 24 weeks
|
according to the results of ultrasound of the mammary glands and / or mammography
|
24 weeks
|
complete pathomorphological response
Time Frame: 24 weeks
|
according to the Miller-Payne classification
|
24 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
change of the Ki67 level in postoperative material compared to primary biopsy
Time Frame: 24 weeks
|
compared to primary biopsy
|
24 weeks
|
the frequency of organ-preserving operation after neoadjuvant treatment
Time Frame: 24 weeks
|
in bouth groups
|
24 weeks
|
quality of life
Time Frame: 24 weeks
|
The quality of life questionnaire EORTC QLQ-C30
|
24 weeks
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antirheumatic Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Antineoplastic Agents, Phytogenic
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Antibiotics, Antineoplastic
- Hormone Antagonists
- Estrogen Antagonists
- Estrogen Receptor Antagonists
- Contraceptive Agents, Hormonal
- Contraceptive Agents
- Reproductive Control Agents
- Contraceptive Agents, Female
- Luteolytic Agents
- Cyclophosphamide
- Paclitaxel
- Fulvestrant
- Doxorubicin
- Triptorelin Pamoate
Other Study ID Numbers
- 12345 (Danish Center for Healthcare Improvements)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on The Neoadjuvant Therapy
-
Hongqian GuoActive, not recruiting
-
Mayo ClinicCompletedBreast Cancer | Chemotherapy | Neoadjuvant Therapy | Hormone Replacement TherapyUnited States
-
Shandong UniversityUnknownBreast Neoplasms | Neoadjuvant TherapyChina
-
Wuhan Union Hospital, ChinaRecruitingBreast Cancer | Neoadjuvant TherapyChina
-
Lumicell, Inc.National Cancer Institute (NCI); Massachusetts General HospitalTerminatedBreast Cancer | Neoadjuvant TherapyUnited States
-
Oxford University Hospitals NHS TrustUniversity of OxfordCompleted
-
Cancer Institute and Hospital, Chinese Academy...Chinese Academy of Medical Sciences Cancer Hospital,Shanxi Center; Chinese... and other collaboratorsNot yet recruitingBreast Cancer | Neoadjuvant TherapyChina
-
Zhejiang Cancer HospitalUnknown
-
Kaohsiung Medical University Chung-Ho Memorial...UnknownTo Observe Whether the Fucoidan Can Improve the Quality of Life of the Such Patients Receiving the Neoadjuvant CCRTTaiwan
-
Samsung Medical CenterTerminatedPhase I: To Determine the Maximum Tolerated Dose (MTD) | Phase II: To Assess the Pathologic CR Rate and Feasibility Following Neoadjuvant Chemoradiation Therapy With S1/OxaliplatinKorea, Republic of
Clinical Trials on Ribocyclib, fulvestrant, triptorelin
-
Hospital de Niños R. Gutierrez de Buenos AiresCompletedCentral Precocious Puberty | Sexual PrecocityArgentina
-
Nanjing UniversityUnknownPolycystic Ovary Syndrome | In Vitro FertilizationChina
-
Aristotle University Of ThessalonikiEugonia IVF Unit, Athens, GreeceUnknown
-
Sir Mortimer B. Davis - Jewish General HospitalRecruitingCastration-resistant Prostate Cancer Patients With OligometastasesCanada
-
Genor Biopharma Co., Ltd.RecruitingLocally Advanced or Metastatic Breast CancerChina
-
Cairo UniversityCompleted
-
ChenshilingNational Natural Science Foundation of China; Comprehensive Strategic Cooperation... and other collaboratorsUnknown
-
IVI MadridCompletedOvarian Hyperstimulation SyndromeSpain
-
Masaryk UniversityMinistry of Health, Czech RepublicCompletedHodgkin Disease | Hodgkin LymphomaCzech Republic